Found: 6
Select item for more details and to access through your institution.
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 1, p. 76, doi. 10.1111/bjh.14382
- By:
- Publication type:
- Article
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
- Published in:
- European Journal of Haematology, 2016, v. 97, n. 2, p. 192, doi. 10.1111/ejh.12707
- By:
- Publication type:
- Article
Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S350, doi. 10.1016/j.clml.2017.07.176
- By:
- Publication type:
- Article
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors.
- Published in:
- Oncologist, 2019, v. 24, n. 1, p. 14, doi. 10.1634/theoncologist.2017-0665
- By:
- Publication type:
- Article